Use Of RFID Asset Management Systems For Monitoring Analytical Instrumentation - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Use Of RFID Asset Management Systems For Monitoring Analytical Instrumentation


Pharmaceutical Technology Europe
Volume 22, Issue 9


( HILARY BRODEY/GETTY IMAGES)
The demonstration of the first continuous wave radio generation and transmission of radio signals by Ernst F. W. Alexanderson in 1906 signalled the beginning of modern radio communication and, subsequently, radio frequency identification (RFID). RFID is the convergence of radio broadcast technology and radar, although many of its early developments are not widely known due to the military significance of this technology. Most documented histories of RFID technology trace its development to the radiobased identification systems from World War II, when the British Air Force used radar to distinguish Allied aircraft from enemy aircraft.

Commercial development of RFID began in the late 1960s. Arguably the first and most widespread commercial use of RFID was in the development of electronic article surveillance (EAS) equipment to counter theft. Although this system could only detect the presence or absence of a tag, the tags themselves could be made cost-effectively and provided an effective anti-theft measure — an important application in the early commercialisation of the technology.

Research and development by academic institutions, government laboratories and private companies led to applications for animal tracking, vehicle tracking and automated manufacturing. By the mid 1990s, implantable RFID tags that were initially used to track laboratory animals were being marketed to veterinarians and animal shelters to identify pets.

RFID is now used for hundreds of applications including theft prevention, personnel access systems, automated parking, traffic management and library book tracking, along with the monitoring of assets in supply chain management. In fact, many attendees were focused on finding asset-tracking solutions1 at the recent RFID Journal LIVE! 2010 event in Orlando (Florida, USA). Management of assets using RFID is the key to its application for pharmaceutical laboratories.

RFID technology fundamentals

RFID systems consist of four main elements: the RFID tags, the RFID reader, the antennas and computer network used to connect the readers.2 The tag itself is the building block of RFID, each containing an antenna and a small chip that contains a radio receiver and a modulator to send a signal back to the reader. Tags come in a variety of shapes and sizes allowing them to be implanted into animals and humans, and they can be powered by the incoming radio signal (passive tags) or by a small battery (active tags). The advantage of an active tag is that its reading range and reliability is greater than that of a passive tag; however, passive tags can be much smaller and cheaper to produce and should, in principle, work indefinitely. RFID tags can also either be promiscuous in that any RFID reader (also known as an interrogator) can communicate with it, or secure where the reader requires an authentication credential in order for the tag to respond.

RFID readers work by sending a pulse of radio energy, which is measured using oscillation frequency and power, to a tag and monitoring the tag's response. Certain frequencies require a license to broadcast using this part of the spectrum, though most RFID systems use the so-called unlicensed spectrum, which does not require a radio license. Low-frequency (LF), high-frequency (HF) and ultra-high frequency (UHF) bands are used within RFID systems depending on the application. For example, the FDA has adopted the HF band for RFID systems that are used to monitor prescription drugs. In a simple RFID system, the reader's energy pulse acts simply as an on-off switch for the tag. In more complex systems, the pulse can include commands to the tag, such as instructions to read or write memory for more advanced monitoring.


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
26%
Oversee medical treatment of patients in the US.
12%
Provide treatment for patients globally.
10%
All of the above.
43%
No government involvement in patient treatment or drug development.
10%
Jim Miller Outsourcing Outlook Jim MillerCMO Industry Thins Out
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerFluorination Remains Key Challenge in API Synthesis
Marilyn E. Morris Guest EditorialMarilyn E. MorrisBolstering Graduate Education and Research Programs
Jill Wechsler Regulatory Watch Jill Wechsler Biopharma Manufacturers Respond to Ebola Crisis
Sean Milmo European Regulatory WatchSean MilmoHarmonizing Marketing Approval of Generic Drugs in Europe
FDA Reorganization to Promote Drug Quality
FDA Readies Quality Metrics Measures
New FDA Team to Spur Modern Drug Manufacturing
From Generics to Supergenerics
CMOs and the Track-and-Trace Race: Are You Engaged Yet?
Source: Pharmaceutical Technology Europe,
Click here